-
公开(公告)号：KR101315255B1
公开(公告)日：2013-10-08
申请号：KR1020100051165
申请日：2010-05-31
Applicant: 대한민국 (식품의약품안전처장)
Abstract: 본 발명은 NAT2를 암호화하는 유전자의 프로모터 부위내에 위치한 단일염기다형성(SNP)로부터 특정 일배체형(Haplotype)을 결정하였으며, 이 특정 일배체형(Haplotype)을 분석할 수 있는 상기 유전자 프로모터의 증폭용 프라이머를 포함하는 NAT2 유전자 프로모터의 일배체형 분석키트 및 이를 이용한 분석방법에 관한 것이다. 본 발명에 의하면, 개인간 유전형의 차이에 따른 맞춤의약을 포함하여,
NAT2 에 의하여 대사되는 약물의 개발에 널리 활용될 수 있다.-
公开(公告)号：KR1020130102778A
公开(公告)日：2013-09-23
申请号：KR1020120023880
申请日：2012-03-08
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N33/15 , G01N2800/52
Abstract: PURPOSE: A method for predicting drug response to atomoxetine using the genotype of cytochrome P450 2D6 (CYP2D6) gene is provided to compute a recommended dosage of a drug by each genotype, thereby presenting a proposal on drug approvals in consideration of Korean pharmacogenomics. CONSTITUTION: A method for analyzing the genotype of CYP2D6 gene for predicting drug response to atomoxetine comprises the step of sequencing exon 1 and exon 6 of a gene encoding CYP2D6 from a genomic DNA; detecting single nucleotide polymorphisms (SNPs) in the determined base sequence, wherein 43th base (T) of sequence number 1 (exon 6) is substituted with C (CYP2D6*2) and 100th base (C) of sequence number 2 (exon 1) is substituted with T (CYP2D6*10); and determining if the genotype of CYP2D6 belongs to extensive metabolizer (CYP2D6EM), intermediate metabolizer (CYP2D6IM), or poor metabolizer (CYP2D6PM). [Reference numerals] (AA) Atomoxetine (ng/mL); (BB) Elapse time after injection (hr)
Abstract translation: 目的：提供使用细胞色素P450 2D6（CYP2D6）基因的基因型预测药物对阿托西汀药物反应的方法，以计算每种基因型药物的推荐剂量，从而提出考虑韩国药物基因组学的药物批准建议。 构成：分析CYP2D6基因基因型预测阿托西汀药物反应的方法，包括从基因组DNA测序编码CYP2D6基因的外显子1和外显子6的步骤; 检测确定的碱基序列中的单核苷酸多态性（SNP），其中序列号1（外显子6）的第43位碱基（T）被C（CYP2D6 * 2）和序列号2（外显子1）的第100位碱基（C） 被T（CYP2D6 * 10）取代; 并确定CYP2D6的基因型是否属于广泛代谢者（CYP2D6EM），中间代谢者（CYP2D6IM）或低代谢者（CYP2D6PM）。 （标号）（AA）阿托莫西汀（ng / mL）; （BB）注射后经过时间（小时）
-
公开(公告)号：KR1020130021764A
公开(公告)日：2013-03-06
申请号：KR1020110084225
申请日：2011-08-23
Applicant: 경희대학교 산학협력단 , 대한민국 (식품의약품안전처장)
Abstract: PURPOSE: An intestinal microbial enzyme complex and a method for preparing the same are provided to ensure anti-allergic, anti-inflammatory, anticancer, and anti-aging effects in vitro. CONSTITUTION: An intestinal microbial enzyme complex contains Megasphaera elsdenii, Parabacteroides distasonis, Klebsiella pneumoniae, and Eubacterium rectale in a ratio of 1:1:1:1. The complex has an enzyme activity to one or more substrates selected from the group consisting of p-nitrophenyl-beta-Dglucuronide, p-nitrophenyl-beta-D-xylopyranoside, nitrophenyl-alpha-L-rhamnopyranoside, and pnitrophenyl-beta-D-glucopyranoside.
Abstract translation: 目的：提供肠微生物酶复合物及其制备方法，以确保体外抗过敏，抗炎，抗癌和抗衰老作用。 构成：肠微生物酶复合物以1:1:1:1的比例含有Megasphaera elsdenii，Parabacteroides distasonis，肺炎克雷伯杆菌和直肠杆菌。 该复合物对一种或多种选自对硝基苯基-β-葡萄糖醛酸苷，对硝基苯基-β-D-吡喃木糖苷，硝基苯基-α-L-鼠李糖吡喃糖苷和对硝基苯基-β- 吡喃葡萄糖苷。
-
4.发明公开DNA 바코드를 이용한 한약재 당귀와 한약재 일당귀의 판별법 및 이를 위한 유전자 마커 有权通过使用DNA BARCODE来鉴定安哥拉GIGANTIS RADIX和JAPANESE ANGELICAE RADIX的方法和遗传标记
公开(公告)号：KR1020160090611A
公开(公告)日：2016-08-01
申请号：KR1020150010630
申请日：2015-01-22
Applicant: 대한민국 (식품의약품안전처장)
IPC: C12Q1/68
CPC classification number: C12Q1/6888 , C12Q1/686 , C12Q2600/13
Abstract: 본발명은한약재당귀와한약재일당귀의판별용유전자마커, 삽입및 결실(Indel)의유전적변이의존재여부를검출하기위한프라이머세트, 상기프라이머세트를포함하는한약재당귀와한약재일당귀의판별용조성물또는키트, 및한약재당귀와한약재일당귀를판별하는방법에관한것이다. 본발명에서개발한유전자마커및 이를이용한한약재당귀와한약재일당귀를판별하는방법은 PCR 산물의사이즈크기확인만으로도손쉽게한약재당귀와한약재일당귀를정확히구별할수 있는특징이있다.
Abstract translation: 本发明涉及：用于区分当归的当归和当归的遗传标记物; 用于检测插入和indel的遗传变异是否存在的引物组; 用于区分当归和当归的组合物或试剂盒，其包含引物组; 和当归猕猴桃和当归的区别方法。 本发明的遗传标记和使用其的当归和当归的鉴别方法使得用户仅通过检查PCR产物的大小便可以容易且准确地区分当归和当归。
-
5.发明公开
公开(公告)号：KR1020140037633A
公开(公告)日：2014-03-27
申请号：KR1020120104016
申请日：2012-09-19
Applicant: 덕성여자대학교 산학협력단 , 대한민국 (식품의약품안전처장)
CPC classification number: G01N33/6893 , C12Q1/6837 , C12Q2600/106 , C12Q2600/142 , C12Q2600/158
Abstract: The present invention relates to a biomarker for screening drugs causing nephyrotoxicity and side effects and to a method for screening drugs causing nephyrotoxicity and side effects using the same and, specifically, to a biomarker in which gene expression is commonly increased or decreased for various drugs causing nephyrotoxicity and to a method for screening drugs causing nephyrotoxicity and side effects using the same. The fact that pyruvate kinase isozyme M2 (PKM2) and eukaryotic elongation factor 1-gamma (EEF1G) are effectively increased in a culture medium of human kidney epithelial cell in which nephyrotoxicity is caused by drugs is confirmed, and such result can be effectively used for assessing toxicity using the human kidney epithelial cell. The biomarker of the present invention can be effectively used for monitoring and deciding drugs or chemicals having risks of novel nephyrotoxicity and side effects and can be used as a tool for investigating a mechanism which generates nephyrotoxicity.
Abstract translation: 本发明涉及用于筛选引起肾毒性和副作用的药物的生物标志物，以及用于筛选引起肾毒性的药物的方法和使用该药物的副作用的方法，具体涉及对各种药物引起的基因表达普遍增加或减少的生物标志物 肾毒性和使用其的药物引起肾毒性和副作用的筛选方法。 确认丙酮酸激酶同工酶M2（PKM2）和真核延伸因子1-γ（EEF1G）在由药物引起肾毒性的人肾上皮细胞的培养基中有效增加的事实，并且这样的结果可以有效地用于 使用人肾上皮细胞评估毒性。 本发明的生物标志物可以有效地用于监测和决定具有新型肾毒性和副作用风险的药物或化学品，并且可以用作研究产生肾毒性的机制。
-
Patent Agency Ranking
公开(公告)号：KR1020110133223A
公开(公告)日：2011-12-12
申请号：KR1020100052835
申请日：2010-06-04
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12N9/00 , C12Q1/26 , C12Q1/6844 , C12Q2600/172
Abstract: PURPOSE: A method for predicting DPD(Dihydropyrimidine dehydrogenase) is provided to analyze genetic polymorphism of DPD and to develop a drug metabolized by DPD. CONSTITUTION: A method for analysis of Korean DPD gene haplotype comprises: a step of obtaining exon 13 and intron 13 encoding DPD from genome DNA to determine each base sequence; a step of detecting SNP in the determined each base sequence; and a step of identifying haplotype selected among Hap1 to Hap3 using the detected SNP. A method for predicting Korean DPD comprises: a step of confirming a DPD gene of a person who is tested, among Hap1 to Hap3; and a step of predicting DPD activity using the confirmed haplotype information.
Abstract translation: 目的：提供一种预测DPD（二氢嘧啶脱氢酶）的方法，用于分析DPD的遗传多态性并开发DPD代谢的药物。 构成：分析韩国DPD基因单体型的方法包括：从基因组DNA获得编码DPD的外显子13和内含子13以确定每个碱基序列的步骤; 检测确定的每个碱基序列中的SNP的步骤; 以及使用检测到的SNP鉴定从Hap1至Hap3中选择的单元型的步骤。 用于预测韩国DPD的方法包括：在Hap1至Hap3中确认被测试人的DPD基因的步骤; 以及使用确认的单元型信息来预测DPD活性的步骤。
-
公开(公告)号：KR101668112B1
公开(公告)日：2016-10-21
申请号：KR1020150010630
申请日：2015-01-22
Applicant: 대한민국 (식품의약품안전처장)
IPC: C12Q1/68
Abstract: 본발명은한약재당귀와한약재일당귀의판별용유전자마커, 삽입및 결실(Indel)의유전적변이의존재여부를검출하기위한프라이머세트, 상기프라이머세트를포함하는한약재당귀와한약재일당귀의판별용조성물또는키트, 및한약재당귀와한약재일당귀를판별하는방법에관한것이다. 본발명에서개발한유전자마커및 이를이용한한약재당귀와한약재일당귀를판별하는방법은 PCR 산물의사이즈크기확인만으로도손쉽게한약재당귀와한약재일당귀를정확히구별할수 있는특징이있다.
-
公开(公告)号：KR1020130102776A
公开(公告)日：2013-09-23
申请号：KR1020120023878
申请日：2012-03-08
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N33/15 , G01N2800/52
Abstract: PURPOSE: A method for predicting drug response to celecoxib using the genotype of cytochrome p450 2C9 (CYP2C9) gene is provided to analyze the genotype of CYP2C9 gene for predicting drug response to celecoxib and to present a proposal on drug approvals in consideration of Korean pharmacogenomics. CONSTITUTION: A method for analyzing the genotype of CYP2C9 gene for predicting drug response to celecoxib comprises the steps of: acquiring exon 2 and exon 7 of a gene encoding CYP2C9 from genomic DNA and sequencing exon 2 and exon 7; detecting single nucleotide polymorphisms (SNPs) in each determined base sequence, wherein 101^th base (T) of sequence number 1 (exon 2) in CYP2C9 is substituted with C (CYP2C9*13) and 114^th base (A) of sequence number 2 (exon 7) in CYP2C9 is substituted with C (CYP2C9*3); and determining if the genotype of CYP2C9 belongs to the extensive metabolizer (EM) group or intermediate metabolizer (IM) group using the detected SNP. A method for predicting drug response to celecoxib by each CYP2C9 genotype comprises the steps of: orally administering 120-250 mg of celecoxib to each of the EM group and the IM group; and comparing the area under the concentration-time curve (AUC) by each genotype and computing a dosage of celecoxib by each genotype. [Reference numerals] (AA) Elapse time after injecting (hr)
Abstract translation: 目的：提供使用细胞色素p450 2C9（CYP2C9）基因的基因型预测药物对塞来昔布药物反应的方法，以分析CYP2C9基因的基因型，以预测药物对塞来昔布的反应，并提出考虑韩国药物基因组学的药物批准建议。 构成：分析CYP2C9基因基因型预测塞来昔布药物反应的方法，包括以下步骤：从基因组DNA和测序外显子2和外显子7获得编码CYP2C9基因的外显子2和外显子7; 检测每个确定的碱基序列中的单核苷酸多态性（SNP），其中CYP2C9中序列号1（外显子2）的第101位碱基（T）被C（CYP2C9 * 13）和第114位碱基（A）序列替代 CYP2C9中第2（外显子7）被C（CYP2C9 * 3）取代; 并使用检测到的SNP确定CYP2C9的基因型是否属于广泛代谢（EM）组或中间代谢（IM）组。 预测每种CYP2C9基因型对塞来昔布的药物反应的方法包括以下步骤：向EM组和IM组口服120-250mg塞来昔布; 并比较每种基因型浓度 - 时间曲线下面积（AUC），并计算每种基因型的塞来昔布剂量。 （标号）（AA）注射后经过时间（hr）
-
公开(公告)号：KR101301872B1
公开(公告)日：2013-08-30
申请号：KR1020120015167
申请日：2012-02-15
Applicant: 대한민국 (식품의약품안전처장)
Abstract: 본 발명은 시토크롬 P450 2C19(CYP2C19)를 암호화하는 유전자의 일배체형 분석방법, 분석키트 및 이를 이용한 CYP2C19 효소의 활성예측방법에 관한 것이다. 좀 더 구체적으로, 본 발명은 한국인의 CYP2C19 유전자에 위치한 기존에 알려진 단일염기다형성(SNP)에 더하여 신규의 SNP를 추가 발굴하여, 특정 일배체형(Haplotype) 정보를 확보하였는 바, 이 일배체형을 분석할 수 있는 프라이머를 이용한 일배체형 분석방법, 분석키트 및 이를 이용하여 CYP2C19 효소의 활성을 예측하는 방법에 관한 것이다. 본 발명에 의하면, 란소프라졸 대사에 관여하는 CYP2C19의 약물대사효소 활성 지표로서 일배체형을 제공할 수 있으며, 유사약물의 약동 및 약력학적 특성을 파악함으로써 CYP2C19에 의해 대사되는 의약품의 평가 및 가교시험에 대한 지표로서 활용할 수 있다.
-
公开(公告)号：KR1020120031387A
公开(公告)日：2012-04-03
申请号：KR1020100092900
申请日：2010-09-24
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12Q2600/156 , C12Q2600/172
Abstract: PURPOSE: An analysis kit for haplotypes of a UGT1A1 gene promoter is provided to predict the expression level of the UGT1A1 gene and to develop drugs. CONSTITUTION: A method for analyzing haplotypes of the human UGT1A1 gene comprises: a step of performing PCR using a human UGT1A1 gene promoter or fragment thereof; a step of analyzing the base sequence of a DNA product; and a step of determining the presence of an SNP of -1352 A>C(3676th base of sequence number 8) and -997 G>A(4031th base of sequence number 8).
Abstract translation: 目的：提供UGT1A1基因启动子单体型分析试剂盒，以预测UGT1A1基因的表达水平，开发药物。 构成：分析人UGT1A1基因的单元型的方法，包括：使用人UGT1A1基因启动子或其片段进行PCR的步骤; 分析DNA产物的碱基序列的步骤; 以及确定-1352A> C（序列号8的第3676位）和-997G> A（序列号8的第4031位）的SNP的存在的步骤。
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.023 seconds)
